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Abstract 
Recent advances in tissue engineering have made progress towards the development of 
biomaterials capable of the delivery of growth factors, such as BMPs, in order to promote 
enhanced tissue repair. However, controlling the release of these growth factors on 
demand and within the desired localised area is a significant challenge and the associated 
high costs and side effects of uncontrolled delivery have proven increasingly problematic 
in clinical orthopaedics. Gene therapy may be a valuable tool to avoid the limitations of 
local delivery of growth factors. Following a series of setbacks in the 1990’s, the field of 
gene therapy is now seeing improvements in safety and efficacy resulting in substantial 
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clinical progress and a resurgence in confidence. Biomaterial scaffold-mediated gene 
therapy provides a template for cell infiltration and tissue formation while promoting 
transfection of cells to engineer therapeutic proteins in a sustained but ultimately transient 
fashion. Additionally, scaffold-mediated delivery of RNA-based therapeutics can silence 
specific genes associated with orthopaedic pathological states. This review will provide 
an overview of the current state-of-the-art in the field of gene-activated scaffolds and 
their use within orthopaedic tissue engineering applications. 
1. Introduction 
The current increasing trend in life expectancy will result in a proportional increase in 
musculoskeletal disorders, specifically orthopaedic pathologies, including fractures, bone 
metastases and osteoporosis, as well as a rise in rheumatic diseases such as osteoarthritis 
[1]. As a result, the coming decades will see a demand for more effective orthopaedic 
repair strategies [2]. Although there has been some success with current treatment 
methods, the limited regeneration potential of these approaches has led to the pursuit of 
advanced therapeutics, including those for functional bone and cartilage tissue 
regeneration. One such approach is the use of scaffold-based delivery systems for nucleic 
acid therapies. Introducing specific genetic sequences into a cell can correct for or replace 
a pre-existing gene, modulating their expression, to accomplish the desired effect [3]. 
Gene-activated platforms offer a method of delivering nucleic acid-based therapeutics in 
a sustained and controllable manner, thereby facilitating a safer and more efficient release 
of therapeutic factors. This review highlights ongoing research within the field, with a 
particular focus on gene-activated biomaterials for the promotion of stable cartilage 
formation and enhanced bone repair. 
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2. Orthopaedic Tissue Engineering  
a. Biomaterials 
Biomaterial scaffolds have been used in orthopaedic tissue regeneration with limited 
success, particularly in cartilage repair. Scaffolds provide a 3D matrix that allows for and 
stimulates the attachment and proliferation of cells. Multiple reviews have reported 
extensively on the range of compositions, structures, fabrication methods and properties 
of available biomaterials [4, 5]. Ultimately, there are several tissue-specific 
considerations when selecting a biomaterial for use within orthopaedic tissue 
engineering. Ideally, scaffolds should be biocompatible, with a suitable degradation rate, 
exhibiting a porous architecture. Other factors such as ease of manufacture and handle-
ability are also important with regards to clinical translation [4]. Typically, biomaterial 
scaffolds can be classified as either natural (e.g. collagen, proteoglycans, alginate or 
chitosan), synthetic (e.g. polystyrene, polyglycolic (PGA) acid or poly(lactic-co-glycolic 
acid) (PLGA)) or ceramic (e.g. hydroxyapatite, β-tricalcium phosphate), each 
demonstrating advantages and limitations. Natural materials provide cells with a suitable 
environment for growth and differentiation and while they often lack the desired 
mechanical properties of the tissue, the enhanced cell response may be enough to 
overcome this limitation. Conversely, synthetic materials allow for large-scale 
manufacture, with controllable mechanical properties and degradation rates, however, the 
by-products of degradation can be toxic, and the materials often require further treatment 
to allow for cell infiltration and integration into surrounding tissues. Ceramics on the 
other hand, provide high mechanical stiffness and biocompatibility, however are limited 
by their hard brittle surface [4]. The development of composite scaffolds offer the 
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advantages of combing the mechanical strength of ceramics with the biological activity of 
naturally derived materials. For example, the development of composite biomimetic 
scaffolds comprised of both collagen and hydroxyapatite, natural constituents of bone, 
resulted in increased mechanical strength compared to collagen alone, while maintaining 
the pore structure and bioactivity required to promote healing [6, 7]. While some reviews 
have reported on the successful use of scaffolds for bone and cartilage repair [1, 8-11] 
there are cases where treatment with a biomaterial scaffold alone will not suffice. As 
such, researchers, including our lab at the Royal College of Surgeons in Ireland (RCSI), 
have been investigating the use of biomaterial scaffolds to deliver bioactive therapeutics 
to the site of the defect, further enhancing the therapeutic efficacy of the platform [12].  
b. Bioactive Therapeutics  
Considering the significant role that growth factors play in the maintenance of tissue 
homeostasis, it is unsurprising that these biomolecules possess enormous therapeutic 
potential for use within tissue engineering applications. Multiple factors have 
demonstrated roles in stimulating chondrogenesis, osteogenesis and angiogenesis [13, 
14]. Due to its potent osteogenic effects, recombinant human bone morphogenetic 
protein-2 (rhBMP-2), is widely studied for bone regeneration and is currently approved 
for use in patients. However, there remain concerns over the safety of rhBMP-2 and its 
association with unwanted side effects including carcinogenicity [15, 16]. Several other 
signalling molecules have been recognised for their beneficial role in bone repair [17]. 
These include cytokines such as transforming growth factor-beta (TGF-β) [18], insulin-
like growth factor (IGF) [19], as well as fibroblast growth factor (FGF) [20]. 
Angiogenesis plays a vital role in bone regeneration, and angiogenic factors such as 
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vascular endothelial growth factor (VEGF) [21] and platelet-derived growth factor 
(PDGF) [22] have also been shown to encourage successful bone healing. Similarly, 
biomolecules targeting different processes in the development of cartilage have 
demonstrated roles in the management of cartilage disorders [23]. In addition to members 
of the TGF-β superfamily [24], BMP-2 [25], and FGF-2 [26], members of the SOX 
family of transcription factors (SOX5, SOX6 and SOX9), collectively referred to as the 
“SOX-trio”, have been shown to play a vital role in the formation and maintenance of 
cartilage [27]. 
c. Therapeutic Delivery Systems 
Tissue regeneration requires prolonged exposure to bioactive molecules to ensure 
efficacy [10]; however, systemic intravenous administration and high dosage often result 
in undesirable effects in other tissues [28]. As a result, much ongoing research is focused 
on investigating alternative advanced approaches for their delivery.  
Many next-generation biomaterial-based delivery systems aim to promote tissue 
regeneration through the controlled delivery of growth factors, commonly in the form of 
recombinant proteins [29-33]. Incorporation of growth factors into biomaterial platforms 
has demonstrated improved osteogenesis and vascularisation [10], as well as the ability to 
promote stable cartilage formation in joint repair [34]. While the criteria required for 
efficient growth factor delivery is beyond the scope of this review, multiple 
comprehensive reviews have previously been published on this topic [35, 36].  
Of note, two such biomaterial-based delivery systems have been approved for use in bone 
regeneration; INFUSE (Medtronic) and OP-1 (Olympus Biotech – Operations 
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discontinued in 2014), containing rhBMP-2 and rhBMP-7 respectively, both of which are 
incorporated within collagen platforms. Although these products have demonstrated the 
ability to repair bone, some unwanted side effects including heterotopic ossification, and 
even an increased incidence of neurological deficits and cancer in patients, have been 
associated with high dosing strategies, poorly controlled growth factor release and non-
specific delivery [37-39]. These unwanted side effects have led to concerns over the use 
of such products and have resulted in the demand for safer and more efficient delivery 
methods. 
3. Gene Therapy in Orthopaedic Repair  
Recent positive clinical trial outcomes have begun to provide the much sought-after 
evidence of the potential of gene therapies to deliver lasting therapeutic benefit, 
catapulting these therapies back into the limelight [40]. At the turn of the century, early 
outcomes of the treatment of X-linked severe combined immunodeficiency reported 
promising results [41, 42]; however, this clinical trial was ultimately deemed a failure 
after the death of one patient and the development of acute leukaemia in multiple patients 
[43]. Shortly after, another death of an 18-year-old male participating in a pilot study for 
the treatment of ornithine transcarbamylase (OTC) deficiency [44] sent the field of gene 
therapy into a deep freeze. However, recent years have seen a revival of gene therapies 
with a growing number of studies demonstrating both safety and efficiency in treating 
several human diseases [3].  
Advances in our understanding of the underlying biological process involved in these 
therapies have led to the European Medicines Agency approving the human gene therapy 
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product, Glybera [45], as well as the successful use of gene therapy, Strimvelis, in 
treating 18 children suffering from immunodeficiency resulting from adenosine 
deaminase deficiency [46]. Following this, the success stories have continued, so much 
so that 2017 was dubbed “the year of gene therapy breakthroughs” [47] with three 
treatments, Kymriah (Novartis), Yescarta (Gilead Sciences) and Luxturna (Spark 
Therapeutics), all coming to market after Food and Drug Administration (FDA) approval. 
Both Kymriah and Yescarta are immunotherapy approaches involving the introduction of 
synthetic chimeric antigen receptors (CAR) to T-cells for the treatment of acute 
lymphoblastic leukaemia and advanced lymphomas respectively, while Luxturna uses the 
direct injection of adeno-associated viral vectors expressing retinal pigment epithelium-
specific protein for the treatment of rare retinal disorders. 
While gene therapy is often associated with the treatment of rare or life-threatening 
genetic disorders, recent progress has shown that it also offers promise for more common 
applications such as the treatment of orthopaedic disorders, as evidenced by the recent 
approval of a gene therapy for osteoarthritis, InvossaTM, in South Korea. This treatment 
consists of a mixture of non-transformed and ex vivo retrovirally transduced chondrocytes 
for the overexpression of TGF-β1 and has demonstrated improvement in both the bone 
area and cartilage thickness in knee osteoarthritis with patients reporting a reduction in 
pain and increased patient quality of life compared to the placebo control [48]. 
Several small and large animal studies have also demonstrated the success of gene 
therapy for the treatment of bone and cartilage defects, with treatments focused mainly on 
the delivery of genes encoding for morphogenetic proteins [49]. Promising studies 
include the direct injection of adenovirus carrying BMP-2 demonstrating repair of 
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femoral defects in rodents [50]. Additionally, the ex vivo modification of cells for the 
overexpression of the angiogenic factor VEGF has demonstrated repair within rabbit 
tibiae [51], as well as the overexpression of the osteogenic factors BMP-2 [52] and BMP-
4 [53] enhancing bone repair in both femoral and skull defects, respectively. With regards 
to cartilage repair, the direct delivery of recombinant adeno-associated viral vector 
(rAAV) with IGF-1[54], FGF-2 [55], or SOX 9 [56], has demonstrated enhanced repair in 
rabbits. Additionally, the genetic modification of chondrocytes or chondroprogenitors for 
the overexpression of TGF-β1 has resulted in the successful repair of osteochondral 
defects in a rodent [57], equine [58], and human defect model (human cartilage biopsies) 
[59]. 
Although these gene therapy approaches have demonstrated varying degrees of 
successful regeneration in bone and cartilage defects, consensus on the safest and most 
efficient delivery method remains unclear. Foreign genetic material is rapidly degraded 
by nucleases and is negatively charged making cell uptake difficult [60]. While the use of 
delivery vectors protects the genetic cargo and improves cellular uptake, rapid clearance 
of these vectors results in short therapeutic timeframes [61]. As an alternative, the use of 
3D porous scaffold-based delivery systems in combination with vectors complexed with 
nucleic acid therapies demonstrate significant advantages over conventionally used 
delivery methods [12, 62, 63]. The delivery vector protects the genetic cargo from 
degradation by serum nucleases, while association of the vectors within the 3D 
microenvironment of the scaffold can prevent the clearance of complexes from the target 
site, allowing for a sustained therapeutic effect, with studies demonstrating bioactivity of 
released genetic cargo over a prolonged period (e.g. 3-6 weeks in vitro) [61].  
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4. Gene-activated Scaffolds for Orthopaedic Tissue Engineering 
a. Scaffold-mediated delivery of DNA 
i. Bone 
The first scaffold-based gene delivery system for musculoskeletal defects was reported in 
1996. Collagen scaffolds containing genes encoding for BMP-4 and pTH1-34, a plasmid 
coding for a fragment of parathyroid hormone (amino acids 1-34), were implanted into 
rat femoral defects resulting in new bone formation and the bridging of large segmental 
defects [64]. Following this, it was demonstrated that these platforms were capable of the 
retention of plasmid (p)DNA for up to six weeks in addition to inducing the formation of 
new bone in a canine tibial defect model in a manner dependent on time, plasmid dose, 
and defect gap size [65]. However, the direct incorporation of the genetic material into 
this scaffold required very high doses (up to 100 mg per scaffold) to exert a therapeutic 
effect [65, 66].  
Delivery vectors can be used to overcome the requirement for high doses, ultimately 
improving the efficiency and therefore efficacy of the delivery system. Viral approaches 
demonstrate an efficient method of gene transfer; however, safety concerns such as 
insertional mutagenesis surround the use of these vectors limiting their clinical 
translation. Non-viral vectors are a relatively safer alternative, potentially having a 
clearer route to clinical translation in tissue regeneration [67]. However, non-viral vectors 
are typically hindered by low transfection efficiency and therefore efficacy. As such, a 
body of research is currently being carried out to enhance their efficiency through their 
incorporation into biomaterial scaffolds (Figure 1). 
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Combining non-viral vectors complexed with pDNA within a biomaterial scaffold 
facilitates enhanced gene transfer [68] and advancements in delivery methods over the 
last two decades have resulted in a reduction in the dose required from the milligram 
range (mg), reported in earlier studies, to the microgram range (µg) (Figure 2). The 
incorporation of a calcium phosphate-pDNA (40 µg) precipitate mixed with collagen 
demonstrated enhanced efficiency of reporter plasmids in vivo [69]. Huang et al., 
demonstrated that condensing BMP-4-pDNA (200 µg) with a non-viral vector such as 
polyethyleneimine (PEI) before incorporation into a PLGA scaffold promoted enhanced 
bone formation in a rat cranial defect model compared to treatment with scaffolds 
incorporating uncondensed pDNA (200 µg )[70]. Following this, Curtin et al., developed 
an innovative osteoconductive and osteoinductive, biodegradable collagen 
nanohydroxyapatite (nHA) gene-delivery platform capable of stimulating mesenchymal 
stem cells (MSCs) towards the osteogenic lineage using as little as 1-5 µg of BMP-2-
pDNA [63]. 
Gene-activated scaffolds also allow for the incorporation and subsequent administration 
of more than one gene into target cells for a potentially heightened synergistic effect. Co-
delivery of PEI-pDNA nanoplexes containing FGF-2 and BMP-2 (5 µg pDNA) 
significantly increased osteogenesis in human adipose-derived MSCs in vitro compared 
to the delivery of either gene alone [71]. This combination of genes when embedded in a 
collagen scaffold was shown to be effective at regenerating bone in rodents with a 
diaphyseal long bone radial defect compared to treatment with PEI-pBMP-2 or PEI-
pFGF-2 collagen scaffolds alone [72]. Interestingly, the model used in this study was a 
diabetic rat model, and the author suggests that these scaffolds could be advantageous in 
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promoting bone regeneration in diabetic patients. However, it is important to note that co-
delivery does not always result in the desired synergistic effect. Following on from a 
study that demonstrated effective bone regeneration using a PDGF-B (1 µg pDNA) 
collagen-based platform [73], D’Mello et al., carried out a pilot study, which investigated 
the co-delivery of the pro-angiogenic plasmid pVEGF with pPDGF-B. However, unlike 
the delivery of pPDGF-B alone, scaffolds incorporating pVEGF either alone or in 
combination with pPDGF-B (1 µg pDNA each) failed to restore the bone defect [74]. 
Tissue engineering approaches should mimic the natural processes involved in tissue 
formation, and combinational gene therapy, delivering multiple genes can maximise 
regeneration. For example, the delivery of both pVEGF and pBMP-2 can recapitulate 
osteogenic-angiogenic coupling observed in bone development. Bone is highly 
vascularized, and the ability of a scaffold to enhance new blood vessel formation is 
critical to the successful repair of defects and disorders. Recent work from our lab 
compared the use of two different non-viral vectors, PEI and nHA, and investigated their 
ability to deliver both pVEGF and pBMP-2 alone and in combination. Results indicated 
that the delivery of both pVEGF and pBMP-2 by the nHA vector combined with a 
collagen-based scaffold exhibited the best healing profile [75]. This study again 
demonstrates that combinational gene delivery is a promising approach for efficient 
tissue repair; however, it also highlights that the ultimate therapeutic success is 
influenced by the choice of the vector [76]. More recently, a chitosan-based vector 
delivering both pBMP-2 and pVEGF (1 µg each) on a collagen-hydroxyapatite scaffold 
resulted in the complete bridging of critical-sized rat calvarial defects within 28 days 
without the detection of off-target side effects. This study focused on the 
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neovascularisation induced by pVEGF, demonstrating that it plays a critical role in bone 
regeneration as the delivery of both pVEGF and pBMP-2 resulted in enhanced bone 
formation compared to the delivery of pBMP-2 alone [77-79].  
ii. Cartilage 
By varying the scaffold composition, genetic material and vector within these platforms, 
gene-activated scaffolds have demonstrated the potential for use in the treatment of 
cartilage defects. TGF-β1 plays an essential role in the formation, growth, maintenance, 
and repair of articular cartilage [80, 81]. Tong et al. demonstrated the ability of scaffolds 
loaded with pTGFβ1 (1 µg, 2 µg or 4 µg per 1 mg scaffold) to act as a bioreactor (in 
vitro) for the production and secretion of collagen type-II and aggrecan by human bone 
marrow stem cells (hBMSCs) [82]. PLGA scaffolds filled with fibrin gel and the use of 
either N,N,N-trimethyl chitosan chloride (TMC) [83] or poly(ethylene oxide)-b-poly(L-
lysine) (PEO-b-PLL) complexes [84] for the delivery of TGF-β1 (1 mg/ml), also 
demonstrated repair of both cartilage and osteochondral defects respectively in rabbits 
after 12 weeks.  
A recent exciting development within cartilage repair is the use of gene-activated 
platforms that target specific aspects of the pro-inflammatory environment found in 
injured or diseased joints. The pro-inflammatory cytokine, interleukin 1 (IL-1), was 
shown to inhibit the chondrogenic development of cells seeded on a 3D woven poly (ε-
caprolactone) (PCL) scaffold [85]. Following this discovery, a gene-activated scaffold for 
the overexpression of an IL-1 receptor antagonist demonstrated the formation of cartilage 
with mechanical properties similar to that of native articular cartilage [86, 87]. These 
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studies highlight the promise for the use of gene-activated scaffolds capable of inducing 
the production of anti-inflammatory molecules or controlling the activation of pro-
inflammatory cytokines within the diseased or injured joint. However, further reseach 
into the regulation of inflammation will be required. 
b. Scaffold-mediated delivery of RNA 
Conventionally, gene therapy involves the induction of genes in the form of pDNA. 
However, state-of-the-art gene therapy has advanced to incorporate the use of RNA-
based therapeutics, opening the door to a range of different targets and approaches for use 
within tissue regeneration including the ability to silence specific genes associated with 
pathological states in orthopaedics.  
The use of RNA-based therapeutics eliminates the requirement for nuclear entry, often 
regarded to be the rate-limiting step in the delivery of pDNA-based therapeutics, as the 
plasmid must enter the nucleus to gain access to the machinery required for transcription 
[88]. RNA-based therapeutics offer several exciting approaches to gene therapy as RNA 
molecules such as messenger (m)RNA, small interfering RNA (si)RNA, short hairpin 
(sh)RNA, and micro (mi)RNA are involved throughout the transcriptional, regulatory and 
other functional activities of the cell. The use of these RNA molecules completely avoids 
the risk of insertional mutagenesis, although delivery of RNA is often hampered by its 
susceptibility to degradative enzymes, which present a significant limitation to its use. 
Recent studies have however reported the successful use of chemically modified mRNA 
demonstrating the enhanced stability of mRNA [73, 89]. The incorporation of chemically 
modified mRNA within biomaterial scaffolds demonstrated enhanced bone formation in a 
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rat calvarial bone defect model compared to pDNA-activated scaffolds [90]. Chemically 
modified mRNA encoding BMP-2 complexed with PEI induced enhanced BMP-2 over-
expression by cells, ultimately resulting in enhanced Bone Volume/Tissue Volume 
(BV/TV) and greater defect bridging, compared to plasmid BMP-2 delivered by similar 
methods [90].  
Other studies have supported the ability of chemically modified BMP-2 RNA to induce 
repair. Bone marrow and adipose-derived MSCs were transfected with chemically 
modified BMP-2 RNA, using lipofection and magnetofection procedures, resulting in 
new bone formation in a rat femoral defect model [89]. Further to this, the use of 
chemically modified mRNAs encoding for various BMPs has also demonstrated the 
promotion of bone regeneration in vivo when delivered using a fibrin gel. Chemically 
modified BMP-9 RNA demonstrated enhanced osteogenic differentiation by BMSCs in 
rat calvarial defect models, as evidenced by increased bone matrix production, with the 
connectivity of the newly formed bone greater following treatment with BMP-9 RNA 
compared to the delivery of BMP-2 RNA [91].  
A particularly exciting approach to RNA-based therapeutics and scaffold-mediated 
delivery is the use of RNA molecules for the manipulation of the RNA interference 
pathway (RNAi), a naturally occurring mechanism, ultimately allowing for the silencing 
of specific genes [92]. The induction of RNA in the form of siRNA and microRNA 
allows for the targeting and degradation of specific mRNA sequences resulting in post-
transcriptional gene silencing. The ability to silence specific genes represents a promising 
therapeutic approach for various orthopaedic disorders (Yin et al., 2014). A 
comprehensive review of scaffold-based microRNA delivery in regenerative medicine 
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was recently published by our lab [88]. Here, in addition to highlighting scaffold-based 
miRNA delivery, we also review some exciting scaffold-based delivery approaches using 
siRNA for the regeneration of cartilage.  
Recently, our lab has demonstrated successful delivery of miRNA therapeutics from 
collagen-based scaffolds for sustained periods [94]. Delivery of miRNA therapeutics 
which either mimic (miR-mimics) or block (antagomiRs) the function of endogenous 
miRNAs, allows for the opportunity to modulate gene expression, depending on the 
specific application. Scaffolds incorporating an antagomiR blocking the function of miR-
133a, an inhibitor of RunX2 expression, resulted in increased bone repair. Enhanced 
osteogenesis was confirmed by the upregulation of a series of osteogenic markers 
including enhanced expression of RunX2 itself, as well as an increase in osteocalcin 
expression and mineral deposition (in vitro) compared to gene-free scaffolds and 
scaffolds containing a scrambled antagomiR (Figure 3) [93].  
Similarly, the use of RNAi allows for enhanced osteogenesis by silencing proteins that 
negatively regulate osteogenesis. Overexpression of Noggin, an antagonist of BMP 
activity, impairs bone formation and siRNA silencing of Noggin demonstrated enhanced 
osteogenic differentiation of hMSCs [95]. Interestingly, within the same study, the co-
delivery of the siRNA with a miRNA (miRNA-20a), inhibiting the expression of 
peroxisome proliferator-activated receptor gamma (PPAR-ɣ), a negative regulator of 
BMP-2 signalling, did not outperform the delivery of the silencing of Noggin by siRNA 
alone [61].  
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In the case of cartilage repair, a recent review highlights the wide range of known anti-
chondrogenic factors and the potential of RNAi based therapies for enhanced 
chondrogenesis and cartilage repair [96]. Although there has been success in the 
development of scaffolds for cartilage repair, very few studies have combined the 
therapeutic potential of RNAi with these delivery systems and the use of RNAi-activated 
scaffolds remains an emerging area of research. One such study demonstrating the 
potential therapeutic application of advanced RNA-based delivery systems is a set of in 
vitro and in vivo studies aimed at silencing an anti-chondrogenic regulator, miRNA-221. 
Alginate pellets formed by hMSCs transfected with antagomiR-221, capable of silencing 
miRNA-221, demonstrated cartilage regeneration in vivo further highlighting the 
therapeutic potential of harnessing the RNAi pathway [97]. A major problem associated 
with in vitro expanded articular chondrocytes is that they tend to form fibrocartilage 
rather than the mechanically superior hyaline articular cartilage. One study described the 
delivery of siRNA targeting the COL1A1 gene in chondrocytes, demonstrating an 
improvement in the ratio of COL2A1, predominant in hyaline cartilage, compared to 
COL1A1, predominant in fibrocartilage, indicating a possible therapeutic for use in 
combination with autologous chondrocyte implantation procedures [98]. Similar work 
was also carried out on MSCs, with, siRNA-targeting COL1A1 having a positive effect, 
inducing more type II collagen expression over type I collagen. However, when 
implanted in vivo, the neo-cartilage tissues underwent endochondral ossification 
regardless of treatment [99]. Novel methods of controlling MSC differentiation is an area 
of research within our lab and many more labs worldwide. 
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5. Future perspectives 
Since the first reports of a gene-activated matrix as an alternative method for 
musculoskeletal gene therapy [64], much excitement has followed this area of research. 
Scaffold-mediated gene therapy offers a promising opportunity to overcome the 
limitations associated with the local delivery of growth factors. Gene-activated platforms 
not only act as a template for cell infiltration and tissue formation but also enable 
autologous host cells to take up specific genes and engineer therapeutic proteins in a 
sustained but ultimately transient fashion. The introduction of genes in the form of 
plasmid DNA allows for gene expression and downstream therapeutic protein production, 
providing an enhanced therapeutic response. Alternatively, scaffold-mediated delivery of 
RNA molecules may be used for the silencing of specific genes associated with the 
negative regulation of tissue regeneration.  
The regulatory landscape is also beginning to become clearer which should ensure a more 
transparent route to the market for these new novel therapeutics. For example, in Europe, 
these activated scaffolds, in particular those delivering pDNA, are likely to be classified 
as advanced therapy medicinal products (ATMPs) as defined by EC Regulation 
1394/2007 [100]. Due to the complexity and innovative nature of such products relative 
to traditional medicinal products, new approaches to manufacturing and GMP are 
required in order to accelerate translation to the clinic. These challenges have been 
recognized by the regulator as reflected in the publication of the European Commission 
‘Guidelines on GMP specific to ATMPs’ Nov. 2017 [101].  
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The field of genetic therapies is exploding and advances in the last two decades have led 
to a resurgence in the use of gene therapies with these approaches being applied to a 
number of regenerative medicine applications. In the last 5 years, 762 clinical trials 
related to gene therapy have been approved, ongoing or completed worldwide, with 2017 
having the most ever in a single year (220 trials) [102]. With this ever-growing 
popularity, it is expected that more gene therapies will be become available for 
orthopaedic applications in the coming years. Further to this, the recent FDA and EMA 
approval of Onpattro (Patisiran) in 2018 (marketed by Alnylam), the first ever non-viral 
RNA-based gene therapy, for the treatment of peripheral nerve disease caused by 
hereditary transthyretin-mediated amyloidosis (hATTR), further highlights the exciting 
therapeutic potential of RNA-based therapies. Additionally, the announcement by the 
FDA Commissioner Scott Gottlieb, M.D in July 2018, on the new framework for the 
development, review and approval of gene therapies, holds great promise in shaping the 
future of medicine. This “fast-tracking” of gene therapies by regulatory bodies, [103] 
along with the recent approval of several gene therapies and the first clinical case of 
scaffold-based gene delivery [104], will only further enhance the on-going drive among 
researchers for the creation and clinical approval of novel therapeutic strategies such as 
those described throughout this review.  
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Figures 
1. Gene-activated scaffold outline. Delivery vectors can be used to package and 
protect nucleic acid cargoes (such as pDNA, mRNA, siRNA, miRNA) facilitating 
cellular uptake. Vector-nucleic acid complexes are contained within the 
biomaterial scaffold. The scaffold itself provides structural support for the 
deposition of new functional tissue while infiltrating cells 
(endogenous/exogenous) engulf the complexes, internalising the genetic cargo, 
resulting in a modification of downstream protein expression. Image adapted from 
[12].  
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2. Refinements in the components of scaffold-based delivery of nucleic acid 
therapeutics over the last two decades has resulted in the reduction of DNA dose 
required for efficient bone repair from milligrams (mg) to micrograms (µg). 
Research into improving the efficiency of non-viral vectors, combinational 
therapies and advanced plasmid design have led to more efficient delivery 
methods requiring lower and relatively safer doses of pDNA. 
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3. AntagomiR-133a activated gene scaffolds for bone tissue engineering. Scaffold 
mediated miR-133a inhibition by antagomiR-133a (a) resulted in increased 
calcium deposition in a hMSCS 3D in vitro culture over 28 days compared to 
gene-free scaffolds and scaffolds containing scrambled antagomiR. (b) Increased 
calcium deposits were observed with alizarin red staining at day 14 and day 28 in 
antagomiR-133a loaded scaffolds compared to controls. Figure re-used and 
adapted from [93]. 
 
